Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. (not Altimmune, Inc.) on April 3, 2012, reporting events occurring on March 30, 2012. The filing discloses the entry into a material definitive agreement involving a new senior secured debt facility.
Key Financial Metrics and Debt Structure
- Total Facility: A senior secured debt facility consisting of a $2.5 million term loan and a revolving line of credit up to $5 million.
- Funding Received: $2.5 million term loan funded (approximately $2.4 million net of expenses) and an initial draw of $858,000 on the line of credit.
- Interest Rates: Term loan fixed at 10.14% per annum; Line of Credit adjustable at 3-month LIBOR (floor 1.5%) plus 5% (6.5% as of March 30, 2012).
- Maturity: Both facilities mature in September 2015.
- Repayment Terms: Term loan is interest-only for the first 10 months (extendable to 12 months), followed by full amortization.
- Prepayment Penalty: 3% of outstanding principal if prepaid in the first two years; 2% thereafter.
- Collateral: Secured by substantially all company assets, including proceeds from intellectual property, though the IP itself is generally excluded.
- Equity Component: Issuance of a warrant to an affiliate of GE Capital to purchase 46,584 shares of common stock at $1.61 per share.
Material Changes
The primary material change is the incurrence of new indebtedness and the creation of a direct financial obligation. The company has moved from its prior capital structure to one including a secured debt facility with GE Capital as the agent. This introduces new covenants limiting acquisitions, dispositions, and further indebtedness.
Outlook, Risks, and Contingencies
- Covenants: The agreement includes customary representations, warranties, and covenants. Breach of these could trigger an event of default.
- Default Consequences: Events of default (including insolvency or bankruptcy) result in automatic acceleration of debt. Lenders may take possession and dispose of collateral.
- Liquidity Impact: The facility provides immediate liquidity through the term loan and access to up to $5 million based on qualified accounts receivable.
- Financial Statements: The filing text does not provide updated revenue, profit, or cash flow metrics for the period; it focuses solely on the debt transaction.
Investor Verification Checklist
- Verify the company name is PharmAthene, Inc., as the filing metadata referenced Altimmune, Inc. incorrectly.
- Review the full text of the Loan and Security Agreement (Exhibit 10.1) for specific financial covenants and definitions of "qualified accounts receivable."
- Assess the impact of the 10.14% interest rate on future cash flow projections.
- Confirm the status of the warrant exercise price ($1.61) relative to the current market price of the stock.
- Monitor compliance with the interest-only period and subsequent amortization schedule to ensure no default occurs.